Monday, January 17, 2011

2011 Immunogenicity for Biotherapeutics Brochure Now Available!

At Immunogenicity for Biotherapeutics, coming up this April 4-6, 2011, in Washington, DC, get practical insights from more than 30 new case studies including how to assess the clinical impact of protein aggregates and pre-existing antibody for correlation with clinical safety and the highly anticipated white paper from UIPS on aggregates, breakage of tolerance and the role of CD4+ T cells.

12 Reasons to Attend the 12th Annual Immunogenicity Event
→ 10 Poster Sessions to Expand Scientific Discussions
→ 5 Perspectives Comparing FDA and EMEA Guidelines
→ 4 Panel Discussions Revealing Industry Tools to Reduce Immunogenicity
→ 7 Countries Represented for Global Regulatory and Pharmaceutical Perspectives
→ 4 New Technology Comparison Case Studies
→ 10 Round Table Subject Matter Expert Opportunities
→ 3 Hour workshop on Strategies for Immunogenicity Assessment of Biosimilars
→ 30 Biopharmaceutical Companies Represented
→ 3 Hours Dedicated to the Fundamentals of Immunogenicity Studies
→ 5 Approaches for Accurately Predicting Immunogenicity
→ 6 White Paper Authors Provide Clear Recommendations
→ 40 Industry Experts Share Best Practices for Immunogenicity Studies

Join speakers from Biogen Idec, Bristol-Myers Squibb, Covance , Pfizer, Genentech, Amgen, Ambrx, Astellas , Meenu Wadhwa, NIBSC, ProFibrix and more!

Download the brochure to find out more about the speakers and presenters at this year's event.
Register here to join us today.

Share this article with your social network, just click below to share now!

No comments :

Post a Comment